Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Prognosis of pancreatic cancer

After the diagnosis is made, the median survival is about 6 months, but shorter if there is liver metastasis. Median survival in operated patients is higher, usually 15-20 months.

In Norway and other western countries, the total five year survival is most often under 5 %.

It is emphasized that cancer in adjacent organs, distal bile ducts, Ampulla of Vater, and the duodenum, can more commonly be operated for cure and have a significantly better prognosis. 

 

 

Five-year relative survival for patients with pancreatic cancer, in percent, during the diagnosis period 1974–2013.

Source: Cancer Registry of Norway

 

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2016